Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Summit, a specialist in oncology, has made excellent clinical progress with its leading candidate, ivonescimab. There's more where that came from, too; Ivonescimab just knocked it out of the park in ...

Q4 2024 Earnings Call Transcript April 30, 2025 PureTech Health plc beats earnings expectations. Reported EPS is $3.98, expectations were $-2.83. Operator: Greetings and welcome to the PureTech Health ...

For most of us, taking Alexandria private is a theoretical exercise. Instead, we must be content with purchasing fractions of ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability.

A short squeeze is a large, short-term spike in a stock's share price that occurs when a significant number of short sellers ...

Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.

Radiopharma biotech Cellectar Biosciences is seeking strategic alternatives, opening the door to further opportunities after ...

Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...

Learn more about Anbio Biotechnology's (NNNN) stock grades for Value and determine whether this Biotechnology stock meets your investment needs.

Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) are two incredibly innovative biotechs, but ...